227 related articles for article (PubMed ID: 30458294)
1. Anti-perlecan antibodies and acute humoral rejection in hypersensitized patients without forbidden HLA specificities after kidney transplantation.
Riesco L; Irure J; Rodrigo E; Guiral S; Ruiz JC; Gómez J; López-Hoyos M; San Segundo D
Transpl Immunol; 2019 Feb; 52():53-56. PubMed ID: 30458294
[TBL] [Abstract][Full Text] [Related]
2. Association of C1q Binding Status With De Novo HLA Antibody Clinical Features and Allograft Function in Kidney Transplantation Patients During Eight Years of Dynamic Follow-up.
Wei X; Yuan X; Sun M; Pan Z; Hu L; Wang L; He J; Hou J
Transplant Proc; 2016; 48(6):1944-54. PubMed ID: 27569927
[TBL] [Abstract][Full Text] [Related]
3. The impact of non-HLA antibodies directed against endothelin-1 type A receptors (ETAR) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Krajewska M; Mazanowska O; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Nowakowska B; Hałoń A; Dawiskiba T; Chudoba P; Klinger M
Transpl Immunol; 2014 Jan; 30(1):24-9. PubMed ID: 24184747
[TBL] [Abstract][Full Text] [Related]
4. Deleterious effect of anti-angiotensin II type 1 receptor antibodies detected pretransplant on kidney graft outcomes is both proper and synergistic with donor-specific anti-HLA antibodies.
Malheiro J; Tafulo S; Dias L; Martins S; Fonseca I; Beirão I; Castro-Henriques A; Cabrita A
Nephrology (Carlton); 2019 Mar; 24(3):347-356. PubMed ID: 29451342
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Antibodies Directed Against Two GPCRs, Anti-AT1R and Anti-ETAR, on Kidney Transplant Outcome.
El Band JEK; Llorente S; Martinez-Garcia P; Alfaro R; Jimenez-Coll V; Boix F; Galián JA; Martinez-Banaclocha H; Botella C; Moya-Quiles MR; Minguela A; Legaz I; Muro M
Curr Protein Pept Sci; 2021; 22(10):745-757. PubMed ID: 34967284
[TBL] [Abstract][Full Text] [Related]
6. Poor graft outcome in recipients with de novo donor-specific anti-HLA antibodies after living related kidney transplantation.
Li X; Ishida H; Yamaguchi Y; Tanabe K
Transpl Int; 2008 Dec; 21(12):1145-52. PubMed ID: 18803618
[TBL] [Abstract][Full Text] [Related]
7. Antibody-Mediated Rejection in Kidney Transplantation Without Evidence of Anti-HLA Antibodies?
Irure J; López-Hoyos M; Rodrigo E; Gómez-Román J; Ruiz JC; Arias M; San Segundo D
Transplant Proc; 2016 Nov; 48(9):2888-2890. PubMed ID: 27932099
[TBL] [Abstract][Full Text] [Related]
8. The influence of non-HLA antibodies directed against angiotensin II type 1 receptor (AT1R) on early renal transplant outcomes.
Banasik M; Boratyńska M; Kościelska-Kasprzak K; Kamińska D; Bartoszek D; Zabińska M; Myszka M; Zmonarski S; Protasiewicz M; Nowakowska B; Hałoń A; Chudoba P; Klinger M
Transpl Int; 2014 Oct; 27(10):1029-38. PubMed ID: 24909812
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation.
Bailly E; Anglicheau D; Blancho G; Gatault P; Vuiblet V; Chatelet V; Morelon E; Malvezzi P; Parissiadis A; Tourret J; Guidicelli G; Sayegh J; Mousson C; Grimbert P; Top I; Le Quintrec M; Purgus R; Westeel PF; Proust B; Chabot V; Lebranchu Y; Dehaut F; Büchler M
Transplantation; 2018 Apr; 102(4):688-698. PubMed ID: 29135832
[TBL] [Abstract][Full Text] [Related]
10. A significant role for anti-human leukocyte antigen antibodies and antibody-mediated rejection in the biopsy-for-cause population.
Banasik M; Kościelska-Kasprzak K; Myszka M; Bartoszek D; Zabińska M; Boratyńska M; Kamińska D; Mazanowska O; Zmonarski S; Krajewska M; Hałoń A; Dawiskiba T; Nowakowska B; Klinger M
Transplant Proc; 2014 Oct; 46(8):2613-7. PubMed ID: 25380878
[TBL] [Abstract][Full Text] [Related]
11. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
[TBL] [Abstract][Full Text] [Related]
12. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
[TBL] [Abstract][Full Text] [Related]
13. Relationship of donor-specific class-I anti-HLA antibodies detected by ELISA after kidney transplantation on the development of acute rejection and graft survival.
Fernández-Fresnedo G; Pastor JM; López-Hoyos M; Ruiz JC; Zubimendi JA; Gonzalez-Cotorruelo J; Rodrigo E; De Francisco AL; Arias M
Nephrol Dial Transplant; 2003 May; 18(5):990-5. PubMed ID: 12686676
[TBL] [Abstract][Full Text] [Related]
14. Clinical relevance of pretransplant anti-HLA donor-specific antibodies: does C1q-fixation matter?
Crespo M; Torio A; Mas V; Redondo D; Pérez-Sáez MJ; Mir M; Faura A; Guerra R; Montes-Ares O; Checa MD; Pascual J
Transpl Immunol; 2013 Dec; 29(1-4):28-33. PubMed ID: 23907088
[TBL] [Abstract][Full Text] [Related]
15. The effect of pregnancy on humoral rejection in patients after vascularized organ transplantation.
Cyganek A; Nowaczyk M; Sańko-Resmer J; Pietrzak B; Grzechocińska B; Pączek L; Międzybrodzki R; Wielgoś M
J Reprod Immunol; 2015 Nov; 112():115-9. PubMed ID: 26469990
[TBL] [Abstract][Full Text] [Related]
16. Screening for de novo anti-human leukocyte antigen antibodies in nonsensitized kidney transplant recipients does not predict acute rejection.
Gill JS; Landsberg D; Johnston O; Shapiro RJ; Magil AB; Wu V; Tinckam K; Keown P
Transplantation; 2010 Jan; 89(2):178-84. PubMed ID: 20098280
[TBL] [Abstract][Full Text] [Related]
17. The prevalence and clinical significance of C1q-binding donor-specific anti-HLA antibodies early and late after kidney transplantation.
Calp-Inal S; Ajaimy M; Melamed ML; Savchik C; Masiakos P; Colovai A; Akalin E
Kidney Int; 2016 Jan; 89(1):209-16. PubMed ID: 26535999
[TBL] [Abstract][Full Text] [Related]
18. Complement-fixing donor-specific anti-HLA antibodies and kidney allograft failure.
Cazarote HB; Shimakura S; Valdameri JS; Contieri FLC; von Glehn CQC; Aita CM; Susin MF; Sotomaior VS; Glehn-Ponsirenas R
Transpl Immunol; 2018 Aug; 49():33-38. PubMed ID: 29596992
[TBL] [Abstract][Full Text] [Related]
19. Anti-glutathione S-transferase T1 antibody-mediated rejection in C4d-positive renal allograft recipients.
Aguilera I; Alvarez-Marquez A; Gentil MA; Fernandez-Alonso J; Fijo J; Saez C; Wichmann I; Nuñez-Roldan A
Nephrol Dial Transplant; 2008 Jul; 23(7):2393-8. PubMed ID: 18308775
[TBL] [Abstract][Full Text] [Related]
20. Clinical implications of angiotensin II type 1 receptor antibodies in antibody-mediated rejection without detectable donor-specific HLA antibodies after renal transplantation.
Lee J; Park Y; Kim BS; Lee JG; Kim HJ; Kim YS; Huh KH
Transplant Proc; 2015 Apr; 47(3):649-52. PubMed ID: 25891704
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
